Orthofix(US:OFIX)2025-11-04 13:30Financial Performance (Q3 2025) - Reported net sales increased by 4.6% to $205.6 million compared to $196.6 million in Q3 2024[2,5] - Pro forma net sales (excluding M6 product lines) increased by 6.3% to $203.4 million compared to $191.3 million in Q3 2024[2] - Bone Growth Therapies net sales increased by 5.7% to $61.2 million[2] - Spinal Implants, Biologics and Enabling Technologies net sales increased by 5.6% to $108.6 million[2] - Global Orthopedics net sales increased by 10.1% to $33.6 million[2] - Adjusted EBITDA increased to $25.114 million, representing 12.2% of reported net sales, compared to $19.180 million or 9.8% in Q3 2024[7] - Pro forma adjusted EBITDA increased to $24.582 million, representing 12.1% of pro forma net sales, compared to $17.515 million in Q3 2024[7] Financial Performance (YTD 2025) - Net sales increased to $602.401 million from $583.834 million[5] - Adjusted EBITDA increased to $55.241 million, representing 9.2% of reported net sales, compared to $43.478 million or 7.4% in YTD 2024[7] - Free cash flow improved to -$18.099 million compared to -$24.285 million in YTD 2024[9] Balance Sheet (September 30, 2025) - Cash and cash equivalents totaled $62.860 million, down from $83.238 million at the end of 2024[3] - Total assets amounted to $832.610 million, compared to $893.294 million at the end of 2024[3]